Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jury Still Out On Beta Amyloid Target In Early Alzheimer’s

This article was originally published in The Pink Sheet Daily

Executive Summary

New data analyses at the Alzheimer’s Association International Congress spur some optimism, but analysts advise caution about whether they will actually translate into clinically meaningful benefits in pivotal trials.

You may also be interested in...



Deal Watch: Boehringer’s Busy Week – An Acquisition, A Divestiture And A Discontinuation

Teva’s buyout of Allergan’s generics business should end speculation about a Teva/Mylan merger. A new Sanofi/Regeneron tie-up and an AstraZeneca divestiture to Sanofi’s Genzyme unit are among the latest developments in immuno-oncology.

Biogen Idec Finalizes Phase III Plans For Aducanumab In Alzheimer’s

Though performance of a middle 6 mg/kg dose cohort just disappointed investors in the Phase Ib PRIME trial, company is confident with using this regimen in two large Phase III studies.

Roche Bullish On Alzheimer’s Prospects

Roche has reported a solid performance for the first half of 2015 and provided a promising, though data-light, R&D update. A number of Phase III starts and filing timelines have been confirmed, and the Swiss pharma also gave an update on its Alzheimer's ambitions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel